中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
9期
118-119
,共2页
骨转移癌%放射治疗%唑来膦酸
骨轉移癌%放射治療%唑來膦痠
골전이암%방사치료%서래련산
Metastasis bone tumour%Radiotherapy%Zoledronic acid
目的:观察放疗联合唑来膦酸对骨转移癌的疗效.方法:将2008年5月-2011年5月本院收治的62例骨转移癌患者分放疗联合唑来膦酸组和单纯放疗组.放疗联合唑来膦酸组第1天应用唑来膦酸4 mg静滴,每4周重复,不少于4次,第2天开始行局部放疗,放疗剂量,常规分割DT 40~50 Gy/20~25次/4~5周;大分割DT 30 Gy/10次/2周;单纯放疗组行单纯局部放疗,观察两组止痛疗效及活动能力改善情况.结果:放疗联合唑来膦酸组止痛效果和活动能力改善情况优于单纯放疗组,比较差异有统计学意义(P<0.05).结论:放疗联合唑来膦酸治疗骨转移癌可提高疼痛缓解率及活动能力,不明显增加毒副作用,值得临床进一步研究.
目的:觀察放療聯閤唑來膦痠對骨轉移癌的療效.方法:將2008年5月-2011年5月本院收治的62例骨轉移癌患者分放療聯閤唑來膦痠組和單純放療組.放療聯閤唑來膦痠組第1天應用唑來膦痠4 mg靜滴,每4週重複,不少于4次,第2天開始行跼部放療,放療劑量,常規分割DT 40~50 Gy/20~25次/4~5週;大分割DT 30 Gy/10次/2週;單純放療組行單純跼部放療,觀察兩組止痛療效及活動能力改善情況.結果:放療聯閤唑來膦痠組止痛效果和活動能力改善情況優于單純放療組,比較差異有統計學意義(P<0.05).結論:放療聯閤唑來膦痠治療骨轉移癌可提高疼痛緩解率及活動能力,不明顯增加毒副作用,值得臨床進一步研究.
목적:관찰방료연합서래련산대골전이암적료효.방법:장2008년5월-2011년5월본원수치적62례골전이암환자분방료연합서래련산조화단순방료조.방료연합서래련산조제1천응용서래련산4 mg정적,매4주중복,불소우4차,제2천개시행국부방료,방료제량,상규분할DT 40~50 Gy/20~25차/4~5주;대분할DT 30 Gy/10차/2주;단순방료조행단순국부방료,관찰량조지통료효급활동능력개선정황.결과:방료연합서래련산조지통효과화활동능력개선정황우우단순방료조,비교차이유통계학의의(P<0.05).결론:방료연합서래련산치료골전이암가제고동통완해솔급활동능력,불명현증가독부작용,치득림상진일보연구.
@@@@Objective:To evaluate the effect of radiotherapy combined with zoledronic acid in patients with tumors of bone metastasis. Method:From May 2008 to May 2011,62 patients with bone metastasis were randomly divided into radiotherapy group(31 patients)and radiotherapy combined with zoledronic acid group(31 patients). Radiotherapy group was only treated by radiotherapy. Radiotherapy combined with zoledronic acid group was treated by zoledronic acid 4 mg,once every four weeks,total 4-6 cycles,and combined with radiotherapy,DT 40-50 Gy/20-25 fx/4-5 w,or DT 30 Gy/10 fx/2 w. Result:For the effect of pain-relief,partial response rate of only radiotherapy group and combination group was 71.0%,93.5%(X2=5.42, P<0.05). There were significant differences between the two groups. And for movement capacity improvement,partial response rate of only radiotherapy group and combination group was 61.3%,83.9%(X2=3.97,P<0.05). There were significant differences between the two groups. Conclusion:Radiotherapy combination with zoledronic acid can improve the patients’ life quality. It is worthy of further clinical trial.